74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
LeMaitre Vascular Inc
Closed
SectorHealthcare
91.61 2.76
Overview
Share price change
24h
Min
88.71
Max
92.27
Income | 43K 11M |
|---|---|
Sales | 898K 56M |
P/E Sector Avg | 43.896 57.333 |
EPS | 0.49 |
Dividend yield | 0.93 |
Profit margin | 20.073 |
Employees | 651 |
EBITDA | 4.6M 20M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +18.19% upside |
Dividend yield Sector Avg | 0.93% 2.63% |
|---|---|
Next Earnings | 1 May 2025 |
Next Dividend date | 29 May 2025 |
Next Ex Dividend date | 14 May 2025 |
Market Cap | -383M 1.9B |
|---|---|
Previous open | 88.85 |
Previous close | 91.61 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
LeMaitre Vascular Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
LeMaitre Vascular Inc Forecast
Price Target
By TipRanks
18.19% upside
12 Months Forecast
Average 105.83 USD 18.19%
High 115 USD
Low 95 USD
Based on 9 Wall Street analysts offering 12 month price targets forLeMaitre Vascular Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
